• Je něco špatně v tomto záznamu ?

Development and extensive analytical validation of deep amplicon sequencing for detecting KRAS and NRAS mutations in metastatic colorectal cancer samples

R. Slavkovský, J. Stránská, V. Věnsková, S. Jančik, L. Kotková, J. Šimová, P. Vojta, P. Flodr, M. Bartoušková, H. Študentová, M. Hajdúch, J. Drábek

. 2022 ; 69 (1) : 203-215. [pub] 20211206

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011561

The presence of wild-type RAS alleles, as determined by genotyping codons 12, 13, 59, 61, 117, and 146, is a prerequisite for personalized anti-EGFR treatment of metastatic colorectal cancer (mCRC) patients. Here we describe analytical validation of in-house developed massively parallel sequencing technology (MPS) in comparison to the in vitro diagnostics (IVD) certified qPCR method. DNA extracted from FFPE samples from CRC patients (n=703) and reference standards (n=33) were tested for KRAS and NRAS mutations in 6 codons of exons 2, 3, and 4 using deep amplicon sequencing (DAS) on a MiSeq benchtop sequencer (Illumina). Two different amplicon lengths and two different library preparation methods (long-RAS and short-RAS) were tested in order to evaluate their impact on DAS performance. In parallel, identical tumor DNA was tested by the following IVD assays: therascreen KRAS RGQ PCR Kit (Qiagen), cobas® KRAS Mutation Test (Roche Diagnostics), and SNaPshot assay (Thermo Fisher Scientific). Both DAS assays detected all the mutations present in reference standards and external quality control samples, except for the artificially generated KRAS codon 146 mutation. The DAS assays performed sufficient analytical specificity and sensitivity (≥0.95). The use of shorter amplicons prolonged the preparation steps but significantly improved the sequencing success rate of FFPE-derived DNA. RAS mutation frequencies in the Czech CRC patients were similar to previous reports, although rare mutations were also detected. DAS with short amplicons is a good strategy for routine assessment of somatic mutations in low-quality FFPE-derived DNA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011561
003      
CZ-PrNML
005      
20231220123109.0
007      
ta
008      
220425s2022 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2021_210907N1276 $2 doi
035    __
$a (PubMed)34881628
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Slavkovský, Rastislav $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital, Olomouc, Czech Republic
245    10
$a Development and extensive analytical validation of deep amplicon sequencing for detecting KRAS and NRAS mutations in metastatic colorectal cancer samples / $c R. Slavkovský, J. Stránská, V. Věnsková, S. Jančik, L. Kotková, J. Šimová, P. Vojta, P. Flodr, M. Bartoušková, H. Študentová, M. Hajdúch, J. Drábek
520    9_
$a The presence of wild-type RAS alleles, as determined by genotyping codons 12, 13, 59, 61, 117, and 146, is a prerequisite for personalized anti-EGFR treatment of metastatic colorectal cancer (mCRC) patients. Here we describe analytical validation of in-house developed massively parallel sequencing technology (MPS) in comparison to the in vitro diagnostics (IVD) certified qPCR method. DNA extracted from FFPE samples from CRC patients (n=703) and reference standards (n=33) were tested for KRAS and NRAS mutations in 6 codons of exons 2, 3, and 4 using deep amplicon sequencing (DAS) on a MiSeq benchtop sequencer (Illumina). Two different amplicon lengths and two different library preparation methods (long-RAS and short-RAS) were tested in order to evaluate their impact on DAS performance. In parallel, identical tumor DNA was tested by the following IVD assays: therascreen KRAS RGQ PCR Kit (Qiagen), cobas® KRAS Mutation Test (Roche Diagnostics), and SNaPshot assay (Thermo Fisher Scientific). Both DAS assays detected all the mutations present in reference standards and external quality control samples, except for the artificially generated KRAS codon 146 mutation. The DAS assays performed sufficient analytical specificity and sensitivity (≥0.95). The use of shorter amplicons prolonged the preparation steps but significantly improved the sequencing success rate of FFPE-derived DNA. RAS mutation frequencies in the Czech CRC patients were similar to previous reports, although rare mutations were also detected. DAS with short amplicons is a good strategy for routine assessment of somatic mutations in low-quality FFPE-derived DNA.
650    12
$a kolorektální nádory $x genetika $7 D015179
650    _2
$a exony $7 D005091
650    _2
$a GTP-fosfohydrolasy $x genetika $7 D020558
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a membránové proteiny $x genetika $7 D008565
650    _2
$a mutace $7 D009154
650    12
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stránská, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Department of Neurology, University Hospital, Olomouc, Czech Republic
700    1_
$a Věnsková, Veronika $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Jančik, Sylwia $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Kotková, Lucie $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Department of Neurology, University Hospital, Olomouc, Czech Republic $7 xx0311825
700    1_
$a Šimová, Jarmila $u CGB Laboratory, Inc., Ostrava, Czech Republic
700    1_
$a Vojta, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Flodr, Patrik $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Bartoušková, Marie $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Department of Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Študentová, Hana $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Department of Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital, Olomouc, Czech Republic
700    1_
$a Drábek, Jiří $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital, Olomouc, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 69, č. 1 (2022), s. 203-215
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34881628 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20231220123105 $b ABA008
999    __
$a ok $b bmc $g 1789261 $s 1162759
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 69 $c 1 $d 203-215 $e 20211206 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace